Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
September 03 2020 - 06:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today announced
an interview with CEO Maria Maccecchini, Ph.D. will air on The
RedChip Money Report television program. The interview will air
Sunday, September 6, at 6 p.m. local time on Bloomberg
International, available in 100+ million homes across Europe.
In the exclusive interview, Dr. Maccecchini
discusses the Company’s new approach to treating neurodegeneration
as well as its active Phase 2a studies in AD and PD.
To view the interview segment, please visit:
https://youtu.be/HlLoZtZs1pg
The interview will also air in the US on the
Family Channel on the Action Channel on Sunday, September 6, at 11
a.m. ET and is available via live stream on American Business
TV.
“The RedChip Money Report" delivers insightful
commentary on small-cap investing, interviews with Wall Street
analysts, financial book reviews, as well as featured interviews
with executives of public companies.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and have commenced a second Phase 2a study in AD and PD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate, including that
clinical trials may be delayed. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2023 to Mar 2024